The Ibogaine Story — Chapter 17: Cures Not Wars
AI-extracted · unverified · confirm at source
Documents May 1994 NIDA Phase I/II protocol design session (60-subject cohort, nested dose run-up). NAS report endorsed ACT UP demands. Molliver primate data: no toxicity 150mg/kg oral. Kappa NDE model, endogenous nor-harman discovery.
Dosing: 150mg, 300mg, 600mg, 900mg, possible 1200mg (nested dose run-up); 150mg/kg oral no toxicity in primates; 50mg/kg i.p. required for ataxia in primates (oral)
Contraindications: Women excluded from initial Phase I/II trial (greater sensitivity across species), HIV+ or TB+ excluded from initial protocol, Seizures observed with intraperitoneal ibogaine injection in primates, Extreme caution in aged (rapid healing from sleep restoration could trigger latent antigens)